-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Biomea Fusion, Inc. (NASDAQ:BMEA) Sees Significant Decrease in Short Interest
Biomea Fusion, Inc. (NASDAQ:BMEA) Sees Significant Decrease in Short Interest
Biomea Fusion, Inc. (NASDAQ:BMEA – Get Rating) was the recipient of a large decline in short interest in August. As of August 15th, there was short interest totalling 353,000 shares, a decline of 21.8% from the July 31st total of 451,600 shares. Currently, 1.5% of the shares of the stock are short sold. Based on an average daily volume of 207,300 shares, the short-interest ratio is currently 1.7 days.
Biomea Fusion Stock Down 5.8 %
Shares of NASDAQ BMEA traded down $0.68 during mid-day trading on Tuesday, reaching $11.06. 59,861 shares of the company were exchanged, compared to its average volume of 173,555. Biomea Fusion has a 52 week low of $2.84 and a 52 week high of $14.85. The stock has a market capitalization of $323.96 million, a PE ratio of -5.29 and a beta of -2.77. The company's 50 day moving average price is $11.44 and its 200 day moving average price is $7.54.
Get Biomea Fusion alerts:Biomea Fusion (NASDAQ:BMEA – Get Rating) last posted its quarterly earnings data on Monday, August 1st. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.60) by $0.01. On average, sell-side analysts predict that Biomea Fusion will post -2.51 earnings per share for the current year.
Insider Activity
In other news, major shareholder A2a Pharmaceuticals, Inc. sold 34,658 shares of the business's stock in a transaction on Thursday, July 21st. The shares were sold at an average price of $11.21, for a total transaction of $388,516.18. Following the completion of the transaction, the insider now directly owns 4,330,684 shares in the company, valued at approximately $48,546,967.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 45.70% of the company's stock.Institutional Trading of Biomea Fusion
Several hedge funds have recently added to or reduced their stakes in BMEA. Northern Trust Corp lifted its stake in Biomea Fusion by 111.3% in the fourth quarter. Northern Trust Corp now owns 173,948 shares of the company's stock worth $1,296,000 after purchasing an additional 91,641 shares during the last quarter. Qube Research & Technologies Ltd bought a new stake in Biomea Fusion in the fourth quarter worth $234,000. DAFNA Capital Management LLC bought a new stake in Biomea Fusion in the fourth quarter worth $2,339,000. Allspring Global Investments Holdings LLC bought a new stake in Biomea Fusion in the first quarter worth $152,000. Finally, JPMorgan Chase & Co. lifted its stake in Biomea Fusion by 19.0% in the first quarter. JPMorgan Chase & Co. now owns 17,382 shares of the company's stock worth $77,000 after purchasing an additional 2,775 shares during the last quarter. 58.19% of the stock is owned by institutional investors.
Analysts Set New Price Targets
A number of research analysts have recently commented on BMEA shares. Piper Sandler reduced their price target on shares of Biomea Fusion from $25.00 to $16.00 in a research report on Friday, May 27th. HC Wainwright reaffirmed a "buy" rating and set a $16.00 price objective on shares of Biomea Fusion in a report on Tuesday, August 2nd.
About Biomea Fusion
(Get Rating)
Biomea Fusion, Inc, a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers.
Read More
- Get a free copy of the StockNews.com research report on Biomea Fusion (BMEA)
- Shock Absorbers: 3 Low Volatility Dividend Stocks for Bumpy Times
- The Retail Sector: Winners And Losers From Q2 Earnings
- Can Targa Continue Rallying To Meet Its Price Target?
- Is Unity Software Ready To Rally After Rejecting AppLovin Offer?
- MarketBeat Podcast: The Time For Cloud Stocks May Be Now
Receive News & Ratings for Biomea Fusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomea Fusion and related companies with MarketBeat.com's FREE daily email newsletter.
Biomea Fusion, Inc. (NASDAQ:BMEA – Get Rating) was the recipient of a large decline in short interest in August. As of August 15th, there was short interest totalling 353,000 shares, a decline of 21.8% from the July 31st total of 451,600 shares. Currently, 1.5% of the shares of the stock are short sold. Based on an average daily volume of 207,300 shares, the short-interest ratio is currently 1.7 days.
Biomea Fusion,Inc.(纳斯达克代码:BMEA-GET Rating)是空头股数8月份股价大幅下跌的接收方。截至8月15日,空头股数共有353,000股,较7月31日的451,600股下降了21.8%。目前,该股1.5%的股份被卖空。以日均成交量207,300股计算,目前短息比率为1.7天。
Biomea Fusion Stock Down 5.8 %
Biomea Fusion股票下跌5.8%
Shares of NASDAQ BMEA traded down $0.68 during mid-day trading on Tuesday, reaching $11.06. 59,861 shares of the company were exchanged, compared to its average volume of 173,555. Biomea Fusion has a 52 week low of $2.84 and a 52 week high of $14.85. The stock has a market capitalization of $323.96 million, a PE ratio of -5.29 and a beta of -2.77. The company's 50 day moving average price is $11.44 and its 200 day moving average price is $7.54.
周二午盘交易中,纳斯达克BMEA的股价下跌0.68美元,至11.06美元。该公司的股票成交量为59,861股,而平均成交量为173,555股。Biomea Fusion的52周低点为2.84美元,52周高位为14.85美元。该股市值为3.2396亿美元,市盈率为-5.29,贝塔系数为-2.77。该公司的50日移动均线价格为11.44美元,其200日移动均线价格为7.54美元。
Biomea Fusion (NASDAQ:BMEA – Get Rating) last posted its quarterly earnings data on Monday, August 1st. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.60) by $0.01. On average, sell-side analysts predict that Biomea Fusion will post -2.51 earnings per share for the current year.
Biomea Fusion(纳斯达克代码:BMEA-GET Rating)上一次公布季度收益数据是在8月1日星期一。该公司公布本季度每股收益(EPS)为0.59美元,比分析师普遍预期的0.60美元高出0.01美元。卖方分析师平均预测,Biomea Fusion本年度的每股收益将达到2.51美元。
Insider Activity
内幕活动
Institutional Trading of Biomea Fusion
Biomea融合的机构性交易
Several hedge funds have recently added to or reduced their stakes in BMEA. Northern Trust Corp lifted its stake in Biomea Fusion by 111.3% in the fourth quarter. Northern Trust Corp now owns 173,948 shares of the company's stock worth $1,296,000 after purchasing an additional 91,641 shares during the last quarter. Qube Research & Technologies Ltd bought a new stake in Biomea Fusion in the fourth quarter worth $234,000. DAFNA Capital Management LLC bought a new stake in Biomea Fusion in the fourth quarter worth $2,339,000. Allspring Global Investments Holdings LLC bought a new stake in Biomea Fusion in the first quarter worth $152,000. Finally, JPMorgan Chase & Co. lifted its stake in Biomea Fusion by 19.0% in the first quarter. JPMorgan Chase & Co. now owns 17,382 shares of the company's stock worth $77,000 after purchasing an additional 2,775 shares during the last quarter. 58.19% of the stock is owned by institutional investors.
几家对冲基金最近增持或减持了BMEA的股份。北方信托公司在第四季度增持了111.3%的Biomea Fusion股份。Northern Trust Corp目前持有173,948股该公司股票,价值1,296,000美元,此前该公司在上一季度又购买了91,641股。Qube Research&Technologies Ltd在第四季度购买了Biomea Fusion的新股份,价值23.4万美元。达夫纳资本管理有限责任公司在第四季度购买了Biomea Fusion价值233.9万美元的新股份。AllSpring Global Investments Holdings LLC在第一季度购买了Biomea Fusion价值15.2万美元的新股份。最后,摩根大通在第一季度将其在Biomea Fusion的持股比例提高了19.0%。摩根大通在上个季度增持了2,775股,目前持有17,382股摩根大通股票,价值77,000美元。58.19%的股份由机构投资者持有。
Analysts Set New Price Targets
分析师设定新的价格目标
A number of research analysts have recently commented on BMEA shares. Piper Sandler reduced their price target on shares of Biomea Fusion from $25.00 to $16.00 in a research report on Friday, May 27th. HC Wainwright reaffirmed a "buy" rating and set a $16.00 price objective on shares of Biomea Fusion in a report on Tuesday, August 2nd.
一些研究分析师最近对BMEA的股票发表了评论。派珀·桑德勒在5月27日星期五的一份研究报告中将他们对Biomea Fusion的股票目标价从25.00美元下调至16.00美元。在8月2日星期二的一份报告中,HC Wainwright重申了买入评级,并为Biomea Fusion的股票设定了16.00美元的目标价。
About Biomea Fusion
关于Biomea Fusion
(Get Rating)
(获取评级)
Biomea Fusion, Inc, a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers.
Biomea Fusion,Inc.是一家生物制药公司,专注于发现和开发共价小分子药物,用于治疗基因定义的癌症和代谢性疾病患者。它的主要候选产品是BMF-219,一种口服生物可用、有效和选择性的薄荷素共价抑制剂,它是多种癌症致癌信号中的转录调节因子。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Biomea Fusion (BMEA)
- Shock Absorbers: 3 Low Volatility Dividend Stocks for Bumpy Times
- The Retail Sector: Winners And Losers From Q2 Earnings
- Can Targa Continue Rallying To Meet Its Price Target?
- Is Unity Software Ready To Rally After Rejecting AppLovin Offer?
- MarketBeat Podcast: The Time For Cloud Stocks May Be Now
- 免费获取StockNews.com关于Biomea Fusion(BMEA)的研究报告
- 减震器:颠簸时代的3只低波动率红利股票
- 零售业:第二季度收益的赢家和输家
- Targa能否继续反弹以实现其价格目标?
- 在拒绝了AppLovin的报价后,Unity Software准备好重整旗鼓了吗?
- MarketBeat播客:云股票的时代可能就是现在
Receive News & Ratings for Biomea Fusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomea Fusion and related companies with MarketBeat.com's FREE daily email newsletter.
接受Biomea Fusion Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Biomea Fusion和相关公司的最新新闻和分析师评级的每日简明摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧